Altimmune, Inc. (ALT)
4.02
-0.06
(-1.47%)
USD |
NASDAQ |
Jan 09, 16:00
4.06
+0.04
(+1.00%)
After-Hours: 20:00
Altimmune Research and Development Expense (Quarterly): 14.93M for Sept. 30, 2025
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Viking Therapeutics, Inc. | 89.95M |
| CorMedix, Inc. | 5.098M |
| Seres Therapeutics, Inc. | 12.62M |
| Rhythm Pharmaceuticals, Inc. | 45.92M |
| Terns Pharmaceuticals, Inc. | 19.92M |